Page 5 of 10 – SEC Filing
Explanatory Note: This Amendment No. 9 relates to and amends the Statement of Beneficial Ownership on Schedule 13D/A (“Schedule 13D/A”) of Tang Capital Partners, LP, a Delaware limited partnership, Tang Capital Management, LLC, a Delaware limited liability company, and Kevin C. Tang, a United States citizen (each, a “Reporting Person” and collectively, the “Reporting Persons”), initially filed jointly by the Reporting Persons with the U.S. Securities and Exchange Commission on August 7, 2014, and amended on September 2, 2014, September 30, 2014, December 16, 2014, May 15, 2015, June 24, 2015, August 21, 2015, March 7, 2016 and March 6, 2017 (as amended, the “Statement”), with respect to the Common Stock, $0.0001 par value (the “Common Stock”), of La Jolla Pharmaceutical Company, a California corporation (the “Issuer”).
Items 3 and 5 of the Statement are hereby amended to the extent hereinafter expressly set forth. All capitalized terms used and not expressly defined herein have the respective meanings ascribed to such terms in the Statement.
Item 3. Source and Amount of Funds or Other Consideration
Item 3 of the Statement is hereby amended to add the following:
On March 23, 2017, Tang Capital Partners, LP purchased 149,254 shares of the Issuer’s Common Stock through an underwritten public offering at a price of $33.50 per share.
On December 11, 2017, Kevin C. Tang, in his capacity as a board member of the Issuer, was granted an option to purchase 10,000 shares of the Issuer’s Common Stock at a price of $28.10 per share, subject to vesting conditions.
On February 23, 2018, Tang Capital Partners, LP purchased 10,000 shares of the Issuer’s Common Stock through the open market at a weighted-average price of $31.5413 per share.
On February 23, 2018, Tang Capital Partners, LP purchased 10,000 shares of the Issuer’s Common Stock through the open market at a weighted-average price of $31.9442 per share.
On February 23, 2018, Tang Capital Partners, LP purchased 10,000 shares of the Issuer’s Common Stock through the open market at a weighted-average price of $32.4186 per share.
On February 23, 2018, Tang Capital Partners, LP purchased 20,000 shares of the Issuer’s Common Stock through the open market at a weighted-average price of $32.58 per share.
On February 23, 2018, Tang Capital Partners, LP purchased 10,000 shares of the Issuer’s Common Stock through the open market at a weighted-average price of $32.3046 per share.
On February 26, 2018, Tang Capital Partners, LP purchased 10,000 shares of the Issuer’s Common Stock through the open market at a weighted-average price of $32.916 per share.
On February 26, 2018, Tang Capital Partners, LP purchased 10,000 shares of the Issuer’s Common Stock through the open market at a weighted-average price of $32.4821 per share.
Follow La Jolla Pharmaceutical Co (NASDAQ:LJPC)
Follow La Jolla Pharmaceutical Co (NASDAQ:LJPC)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
